Intravenous Alpha-Lipoic Acid
IV alpha lipoic acid (ALA) is used to treat cancer (especially pancreatic cancer), neuropathy, insulin resistance and diabetes and chronic liver disease.
It is a powerful antioxidant and helps to protect cells from oxidative damage. ALA plays a significant role in several biological processes in the body. It is considered the “universal antioxidant” since it demonstrates such diverse physiological activity.
Alpha lipoic acid is a free-radical scavenger, quenching DNA- and cell-damaging oxidants. Free radicals cause disease by damaging healthy cells and genetic material. ALA is required for healthy cell metabolism, slowing down the aging process. It stabilizes NF(k)B and discourages the proliferation of malignant cells. ALA helps to regenerate glutathione, a major antioxidant in the body. Glutathione is critical to healthy aging and disease prevention.
The Research on IV ALA
Many preclinical studies have shown that ALA initiate apoptosis (natural cell death) in cancer cells and prevent normal cells from becoming cancerous. Case reports have shown improved survival and improved quality of life in cancer patients treated with ALA in combination with low-dose naltrexone or other antioxidants. A small number of human trials have documented the use of alpha lipoic acid in cancer and chemotherapy-induced peripheral neuropathy, based on a long history of safe and effective use for the treatment of peripheral neuropathy in diabetic patients.
Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases.